In this issue of Cancer Cell, Kopp and colleagues report that pancreatic ductal cells are largely refractory to the induction of pancreatic neoplasia. Whereas a rare ductal subpopulation may still prove capable of neoplastic transformation, these findings refocus attention on acinar and other non-ductal cell types as initiators of this deadly neoplasm.
While malignant tumors of the pancreas can display a variety of histologic forms, the term ''pancreatic cancer'' is usually synonymous with a pathological diagnosis of pancreatic ductal adenocarcinoma (PDAC). As its name implies, PDAC has long been presumed to arise from pancreatic ductal epithelial cells. Along with its noninvasive precursor, pancreatic intraepithelial neoplasia (PanIN), these tumors typically display a distinctly duct-like histology, and express markers of ductal differentiation. As demonstrated for other tumor types, however, tumor histology is often misleading in determining tumor lineage, and work from Kopp et al. (2012) published in this issue of Cancer Cell reinforces the disputed paternity of pancreatic ''ductal'' neoplasia.
Initial clues suggesting that non-ductal cells might serve as effective cells of origin for pancreatic ductal neoplasia were provided by studies involving transgenic misexpression of individual oncogenes under the regulation of nonductal promoter elements, in which a subset of resulting tumors displayed histologic resemblance to adult ductal epithelium (Sandgren et al., 1991) . However, these similarities were ultimately proven to be only skin-deep, as additional studies of PanIN and PDAC revealed activation of transcriptional programs typically observed in embyronic pancreatic epithelium, but not in differentiated duct cells (Miyamoto et al., 2003; Park et al., 2011) .
With the advent of autochthonous mouse models of pancreatic neoplasia, more recent studies have interrogated individual pancreatic cell types for the ability to generate PanIN, based upon Cre/lox-mediated activation of oncogenic Kras. Initial seminal work in this arena utilized either Pdx1
Cre or Ptf1a Cre alleles to activate Kras in embryonic pancreatic progenitor cells (Aguirre et al., 2003; Hingorani et al., 2003) . While these studies demonstrated that embryonic activation of oncogenic Kras effectively initiated pancreatic ductal neoplasia, they provided considerably less information regarding the capacity of individual adult cell lineages to similarly serve as effective cells of origin. Based on the availability of appropriate Cre driver lines, this adult capacity was first interrogated in pancreatic acinar cells. Using either a Nestin-Cre driver to activate oncogenic Kras in exocrine progenitor cells and their acinar cell descendants (Carriè re et al., 2007) or a variety of inducible Cre lines to activate Kras in adult acinar cells (De La O et al., 2008; Guerra et al., 2007; Habbe et al., 2008) , these studies provided strong evidence that acinar cells could indeed serve as effective biologic parents for pancreatic ductal neoplasia. In these studies, the ability of adult acinar cells to generate PanIN was dramatically accelerated in the context of associated pancreatitis, a known risk factor for the human disease. Additional studies suggested that a permissive inflammatory microenvironment could broadly bestow PanIN-parenting capabilities, as even insulin-expressing cells were shown to be capable of generating PanIN in the context of associated pancreatitis (Gidekel Friedlander et al., 2009) .
Ironically, these studies demonstrating that pancreatic ductal neoplasia could be generated from a variety of non-ductal cell types were all completed prior to a similar definitive evaluation in actual ductal epithelial cells. However, a longawaited detailed glimpse at the parental capacities of the ductal epithelial lineage is now available. In this new study, Kopp et al. (2012) (Figure 1 ).
Before entirely disqualifying ductal and centroacinar cells from consideration as capable PanIN parents, it is necessary to consider a broad number of remaining questions and possibilities. First, it must be recognized that, while Sox9 appears to be expressed in a substantial majority of pancreatic ductal and centroacinar cells, there is considerable heterogeneity in gene expression along the ductal epithelial tree, and the distinct possibility remains that PanIN can effectively originate from a subpopulation of Sox9-negative ductal epithelial cells. In addition, the study by Kopp et al. (2012) relied on tamoxifen-induced recombination in only 12% of all Sox9-expressing cells. As acknowledged by the authors, this fraction, when further reduced by a less than uniform response to Kras even among competent cell types, means that rare Sox9-expressing cells (i.e., centroacinar cells) might not have been effectively interrogated in large numbers; perhaps these cells account for the rare PanIN lesion observed in these mice. In spite of these caveats, it remains difficult to escape the authors' primary conclusion that the predominant ductal lineage in adult mouse pancreas remains largely refractory to Kras-mediated transformation.
While it is tempting to extend these findings to the human disease, appropriate caution is warranted. In particular, the current experimental paradigm only evaluates what can happen, i.e., the competence of individual adult murine cell types to generate PanIN in response to oncogenic Kras, as opposed to what actually does happen under conditions of spontaneous or carcinogen-induced human KRAS mutations. Certainly, murine PanIN induced by Kras activation in either embryonic pancreas or in adult acinar cells seems to bear exquisite resemblance to human PanIN, both histologically and with respect to gene expression patterns. However, prior analysis of KRAS sequences in acinar cells adjacent to human PanIN failed to identify mutant alleles (Shi et al., 2009) , suggesting that acinar cell KRAS mutations are either extremely rare or rapidly induce metaplastic or neoplastic conversion to a non-acinar morphology. On the other hand, cells with features of acinar differentiation can often be identified in human PanIN, and a subset of acinar to ductal metaplasia (ADM) do, indeed, harbor KRAS mutations identical to those observed in adjacent PanIN (Shi et al., 2009) . These findings might be consistent with KRAS mutations arising in either acinar cells themselves or in areas of ADM, with subsequent rapid progression to PanIN.
Assuming that these findings are indeed relevant to the human disease, what are the ramifications of the current findings? Certainly, they suggest that future chemoprevention strategies might be best targeted at early events in acinar rather than ductal cells; blocking acinar cell activation of Sox9 now joins Notch pathway inhibition and maintenance of Mist1 expression as examples of such approaches. In addition, these findings underscore an increasingly recognized disconnect between Kras mutations and Kras activity. Along these lines, it will be fascinating to determine the presumably epigenetic determinants underlying the differential responsiveness to oncogenic Kras observed in acinar and ductal cell types; manipulating such determinants may convert acinar cells into less capable parents, hopefully eliminating PanIN from the pancreatic family tree.
Adaptive resistance to PI3K-mTOR inhibitors potentially limits the clinical antitumor activities of these agents. In this issue of Cancer Cell, Britschgi and coworkers show that certain tumors acquire resistance to PI3K-mTOR inhibitors through activation of a JAK2-dependent pathway, leading to interleukin-8 secretion.
More than 25 years have passed since the discovery of phosphoinositide 3-kinase (PI3K) as an oncoprotein-associated enzymatic activity. The term ''PI3K'' in this context designates the Class I subset of phosphoinositide kinases (comprising the a, b, g, and d isoforms), which convert phosphatidylinositol-4,5-bisphosphate to the bioactive second messenger phosphatidylinositol-3,4,5-trisphosphate ( Vanhaesebroeck et al., 2012) . These PI3Ks are activated, directly or indirectly, by a variety of cell surface receptors that include receptor tyrosine kinases (RTKs) and G protein-coupled receptors. Several cardinal alterations elicited by PI3K activation include changes in cell proliferation, survival, migration, and metabolism, and are highly aligned with the ''hallmarks of cancer'' discussed by Hanahan and Weinberg (2011) . Indeed, inappropriate activation of the PI3K pathway has been observed in a remarkably broad array of human cancers. Nested within this prooncogenic signaling network are two pivotal protein serine-threonine kinases, AKT (also termed protein kinase B) and mTOR, both of which represent druggable targets, like PI3K itself. This combination of biological relevance and pharmacological tractability rendered the PI3K pathway an irresistible target for cancer drug discovery. The ensuing efforts in
